Stockscreener 앱 받기
48.60
1.28%
0.634
전일 마감가:
$47.97
열려 있는:
$47.99
하루 거래량:
2.58M
Relative Volume:
0.73
시가총액:
$20.83B
수익:
$2.38B
순이익/손실:
$1.32B
주가수익비율:
27.30
EPS:
1.7806
순현금흐름:
$897.24M
1주 성능:
+3.31%
1개월 성능:
+5.14%
6개월 성능:
+33.77%
1년 성능:
+55.87%
1일 변동 폭
$47.98
$48.75
1주일 범위
$46.06
$48.75
52주 변동 폭
$29.66
$48.75
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
48.63 | 20.55B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
447.67 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
771.50 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
744.92 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.01 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.74 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - The Manila Times
J. Safra Sarasin Holding AG Purchases Shares of 90,035 Royalty Pharma PLC $RPRX - MarketBeat
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - GlobeNewswire Inc.
Trading the Move, Not the Narrative: (RPRX) Edition - Stock Traders Daily
Royalty Pharma stock hits 52-week high at $47.87 By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (RPRX) director granted 815-share equity award - Stock Titan
Denali Therapeutics scores $200 million shortly after first drug approval - The Business Journals
TD Cowen reiterates Royalty Pharma stock Buy rating on lupus drug potential By Investing.com - Investing.com South Africa
Royalty Pharma and J&J partner to develop autoimmune treatment - Yahoo Finance
Royalty Pharma in $500M R&D funding collaboration with J&J - MSN
Royalty Pharma commits $500M to J&J autoimmune drug development By Investing.com - Investing.com India
Royalty Pharma commits $500M to J&J autoimmune drug development - Investing.com
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases - Bitget
Johnson & Johnson taps Royalty Pharma for $500M autoimmune drug push - Stock Titan
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat
Eastern Bank Acquires 263,867 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Wedge Capital Management L L P NC Lowers Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Wealth Enhancement Advisory Services LLC Buys 165,451 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Refreshes Leadership As AI And Asia Shape Valuation Story - Yahoo Finance
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment - ChartMill
RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) - ChartMill
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - MSN
Royalty Pharma EVP Coyne sells shares worth $1.58 million By Investing.com - Investing.com Australia
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 34,791 Shares of Stock - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $1.58 million - Investing.com
Royalty Pharma (RPRX) CFO’s entities sell 34,791 shares under 10b5-1 plan - Stock Titan
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Nordea Investment Management AB Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
How Royalty Pharma’s New AI and Dealmaking Hires Could Shape RPRX’s Royalty Sourcing Strategy - Sahm
Royalty Pharma names Lucas Glass as head of artificial intelligence By Investing.com - Investing.com India
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance UK
Affiliates of RPRX sell multiple blocks of common stock (RPRX) - Stock Titan
Royalty Pharma plc Appoints Lucas Glass as Head of Artificial Intelligence, Effective April 2026 - marketscreener.com
Royalty Pharma names Lucas Glass as head of artificial intelligence - Investing.com
Royalty Pharma plc (RPRX) Latest Stock News & Headlines - Yahoo Finance
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence - The Globe and Mail
How The Royalty Pharma (RPRX) Story Is Shifting With New Deals And Updated Expectations - Yahoo Finance
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
(RPRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
FOMO Trade: Will Royalty Pharma plc benefit from rate cuts2026 Setups & AI Optimized Trade Strategies - baoquankhu1.vn
Royalty Pharma PLC $RPRX Shares Purchased by Tudor Investment Corp ET AL - MarketBeat
S&P 500 Futures Decline In Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Moomoo
S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Royalty Pharma Lag - Barron's
Aug Action: Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Does Royalty Pharma plc have high return on assets2026 Institutional & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Royalty Pharma PLC $RPRX Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M - MSN
RPRX: Entities report multi‑date sell notices including 136,980‑share trade - Stock Titan
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):